TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07812090: A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

Sponsor: BioAge Labs, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,992,000

Rescue Site Savings

+$1,328,000

Unlock Full NCT07812090 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07812090 Rescue Dossier →